Last reviewed · How we verify
HS-10296 po
At a glance
| Generic name | HS-10296 po |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer (PHASE2)
- A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients (PHASE3)
- A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10296 po CI brief — competitive landscape report
- HS-10296 po updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI